首页> 外文期刊>Surgery Today >Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case
【24h】

Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case

机译:FOLFOX4 +贝伐单抗联合术前放化疗后,最初无法切除的局部晚期直肠癌浸润盆腔壁的全直肠系膜切除术:病例报告

获取原文
获取原文并翻译 | 示例
           

摘要

A 60-year-old man underwent sigmoid loop colostomy for obstructive rectal cancer. Computed tomography (CT) showed a circumferential thickening of the lower rectal wall caused by a tumor invading the posterior and side pelvic wall. As we considered R0 resection too difficult, we gave the patient bevacizumab plus FOLFOX4 (oxaliplatin, leucovorin, and 5-fluorouracil). After eight courses, CT showed improvement in the rectal wall thickening but linear thickening of the mesorectal fascia remained. We therefore gave the patient chemoradiotherapy (CRT), and then 10 weeks later performed Hartmann’s operation laparoscopically. Microscopic examination revealed that the tumor had been almost replaced by fibrous tissue, with only a few cancer cells left in the subserosa. The circumferential resection margin was free of cancer cells. The patient is doing well after 27 months of follow-up. This case suggests that systemic chemotherapy with FOLFOX4 plus bevacizumab prior to conventional preoperative CRT is a promising strategy for patients with initially unresectable locally advanced rectal cancer.
机译:一名60岁的男子因梗阻性直肠癌接受了乙状结肠结肠造口术。计算机断层扫描(CT)显示,由于肿瘤侵犯了骨盆后壁和侧壁,导致直肠下壁周向增厚。由于我们认为R0切除术太困难了,我们给了患者贝伐单抗加FOLFOX4(奥沙利铂,亚叶酸钙和5-氟尿嘧啶)。经过八个疗程后,CT显示直肠壁增厚有所改善,但直肠中筋膜仍呈线性增厚。因此,我们进行了患者放化疗(CRT),然后在10周后通过腹腔镜进行了Hartmann手术。显微镜检查显示,肿瘤几乎被纤维组织所取代,浆膜下仅剩少量癌细胞。周缘切除边缘无癌细胞。随访27个月后,患者情况良好。该病例表明,对于最初无法切除的局部晚期直肠癌患者,在常规术前CRT之前使用FOLFOX4加贝伐单抗进行全身化疗是一种有前途的策略。

著录项

  • 来源
    《Surgery Today》 |2012年第1期|75-79|共5页
  • 作者单位

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Medical Oncology Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

    Department of Gastroenterological Surgery Gastroenterological Center Cancer Institute Hospital Japanese Foundation for Cancer Research 3-8-31 Ariake Koto-ku Tokyo 135-8550 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Rectal cancer; FOLFOX4; Bevacizumab; Chemoradiotherapy;

    机译:直肠癌;FOLFOX4;贝伐单抗;放化疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号